Dr. Hwamee Oh, PhD, director of imaging research at the Memory and Aging Program at Butler Hospital and assistant professor in the Department of Psychiatry and Human Behavior at Brown University, has been awarded a National Institutes of Health (NIH) grant. The grant will fund her project on novel cognitive and neuroimaging markers of early Alzheimer’s disease pathologies.
Dr. Oh is a cognitive neuroscientist with expertise in multi-platform imaging that combines functional, structural and diffusion MRI with amyloid and tau PET to detect changes in memory systems with aging and Alzheimer’s disease. In her role at the Memory and Aging Program, Dr. Oh focuses on the use of imaging to detect the development of Alzheimer’s disease before symptoms become apparent, which offers patients the best chance at slowing the progression of the disease through early intervention.
To learn more about the Memory and Aging Program and how you can get involved, visit butler.org/memory.
Explore More from The Memory and Aging Program at Butler Hospital
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
Caregiver to both her young husband and her father with dementia, now she’s supporting others in the caregiver journey.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
RI Chosen as 1 of 5 Sites for First Nationwide Study of Lifestyle Intervention to Reduce Risk of Cognitive Decline
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is sponsored by the Alzheimer’s Association and is the first such study to be conducted in a large, diverse group of Americans across the United States.
Louisa Thompson, Ph.D., research scientist at Brown University and Butler Hospital, will evaluate how app-based and online cognitive tests might be used to detect subtle changes in memory and thinking associated with Alzheimer’s.
Butler Hospital was one of 27 sites across the U.S. to study the drug flortaucipir through a partnership between its Memory and Aging Program and Rhode Island Hospital.